Treatment Options Post Exposure to COVID-19

Introductory content goes here…

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Mauris placerat ullamcorper sem eu sodales. Praesent suscipit mauris nec augue bibendum, ut consequat massa sodales. Proin et lacus enim. Vivamus vulputate luctus ultrices. Quisque consequat porttitor fringilla. Mauris vitae nulla porttitor, gravida diam et, egestas mauris. Mauris convallis metus at urna rutrum, eget hendrerit metus porttitor. Maecenas posuere lorem rhoncus nisi eleifend mollis. 

Web Tip: This has the potential to change everything and give us freedom like that already enjoyed by those vaccinated who have a normal immune system.

CLL Society Organizes Joint Effort Urging Government Agencies to Focus on Continued COVID-19 Protections for the Immunocompromised

In light of the FDA’s announcements regarding the discontinuation of Emergency Use Authorization for both Evusheld  and Bebtelovimab, CLL Society and eight other patient advocacy organizations sent a letter to federal officials requesting them to immediately undertake thirteen specific actions that would help protect the estimated seven million Americans who are immunocompromised against COVID-19.

FDA Announces Evusheld is Not Currently Authorized for Emergency Use in the U.S.

As of 1/26/23, Evusheld (tixagevimab co-packaged with cilgavimab) is no longer available as Pre-Exposure Prophylaxis (PrEP) in the United States. That decision was made because as the virus continued to mutate, now over 90% of SARS-CoV-2 variants of concerns (VOC) circulating in the U.S. are no longer believed to be neutralized by the monoclonal antibody (mAb) cocktail.

CLL Society - COVID-19
RECENT NEWS

When appropriate, the CLL Society will be posting updates and background information on the present Coronavirus pandemic focusing on reliable primary sources of information and avoiding most of the news that is not directly from reliable medical experts or government and world health agencies.